Qiagen reports 4.95 percent stake. Qiagen stock trades EUR 40.02 versus EUR 39.85.

Published on 10/05/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue in the second quarter hit USD 535.04 million versus USD 527.50 million. Qiagen stock costs EUR 40.02 on October 5, 2026 versus EUR 39.85.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) disclosed a voting-rights notification showing Bank of America at 4.95 percent on October 2, 2026, while Qiagen stock was trading at EUR 40.02 at Lang & Schwarz on October 5, 2026 at 12:47 p.m. CEST, plus 0.43 percent versus the EUR 39.85 prior close. The filing gives investors a fresh ownership detail, while the larger operating signal remains the company's second-quarter performance.

Bank of America position reaches 4.95 percent

According to TradingView on October 2, 2026, the notification identified Bank of America Corporation as holding 4.95 percent of Qiagen's capital interest and voting rights. The position consisted of 2.78 percent indirect real holdings and 2.18 percent indirect potential holdings, making the disclosure more detailed than a simple share purchase announcement.

The filing also recorded a transaction date of September 28, 2026. For the market, the key fact is the size of the reported position rather than a change in Qiagen's operating guidance.

Second-quarter revenue beats consensus

Qiagen reported USD 535.04 million of revenue in the second quarter, compared with USD 527.50 million expected, according to MarketBeat on October 2, 2026. The USD 7.54 million gap represents 1.43 percent above consensus, giving the revenue figure a concrete comparison point.

Adjusted earnings per share came in at USD 0.62 versus USD 0.60 expected, a USD 0.02 beat, while the same quarter a year earlier produced USD 0.60 per share, MarketBeat reported. Qiagen's quarterly revenue was up 0.20 percent year over year, and the company set fiscal 2026 earnings-per-share guidance at USD 2.43.

Stock remains below its yearly high

Qiagen's US-listed QGEN shares had a 52-week range of USD 32.53 to USD 57.82 in the finance quote dated October 2, 2026, with a market capitalization of USD 9.2 billion. The euro reference price is a separate Lang & Schwarz quotation, so the two currencies are not combined in a return or distance calculation.

The primary listing is NYSE under ticker QGEN, while the Frankfurt listing is identified as QIA. The company operates in healthcare and medical diagnostics and research, with products spanning sample preparation, molecular testing, instruments and bioinformatics. Makkler lists November 10, 2026 as the next earnings date.

EUR 40.02 keeps the focus on execution

At EUR 40.02, Qiagen stock was trading at Lang & Schwarz on October 5, 2026 at 12:47 p.m. CEST, up 0.43 percent versus the EUR 39.85 prior close from the same venue. The modest daily move puts the emphasis on the 1.43 percent revenue comparison and the 4.95 percent voting-rights disclosure rather than on a large intraday repricing. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.